drugset / Trial / NCT05477095
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in healthy adults.
Timeline
- Start
- 2022-07-06
- Primary completion
- 2023-10-06
- Completion
- 2023-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UB-313 | Peptide | 100 ug | Intramuscular |
| Subject | UB-313 | Peptide | 300 ug | Intramuscular |